1. Chen, Siyu, Wu, Yong, Wang, Simin, Wu, Xiaohua, Zheng, Zhong. 2022. A risk model of gene signatures for predicting platinum response and survival in ovarian cancer. In Journal of ovarian research, 15, 39. doi:10.1186/s13048-022-00969-3. https://pubmed.ncbi.nlm.nih.gov/35361267/
2. Paulin, Denise, Hovhannisyan, Yeranuhi, Kasakyan, Serdar, Li, Zhenlin, Xue, Zhigang. 2020. Synemin-related skeletal and cardiac myopathies: an overview of pathogenic variants. In American journal of physiology. Cell physiology, 318, C709-C718. doi:10.1152/ajpcell.00485.2019. https://pubmed.ncbi.nlm.nih.gov/32023076/
3. Zhang, Shu-Bing, Liu, Yu-Xing, Fan, Liang-Liang, Jin, Jie-Yuan, Xiang, Rong. 2018. A novel heterozygous variant p.(Trp538Arg) of SYNM is identified by whole-exome sequencing in a Chinese family with dilated cardiomyopathy. In Annals of human genetics, 83, 95-99. doi:10.1111/ahg.12287. https://pubmed.ncbi.nlm.nih.gov/30276801/
4. Su, Zhiyong, Wang, Guanghui, Li, Leilei. . CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer. In Cancer biomarkers : section A of Disease markers, 38, 143-159. doi:10.3233/CBM-230028. https://pubmed.ncbi.nlm.nih.gov/37781794/
5. Noetzel, E, Rose, M, Sevinc, E, Knüchel, R, Dahl, E. 2010. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse. In Oncogene, 29, 4814-25. doi:10.1038/onc.2010.229. https://pubmed.ncbi.nlm.nih.gov/20543860/